Correlating metabolic and anatomic responses of primary lung cancers to radiotherapy by combined F-18 FDG PET-CT imaging. (1/445)

BACKGROUND: To correlate the metabolic changes with size changes for tumor response by concomitant PET-CT evaluation of lung cancers after radiotherapy. METHODS: 36 patients were studied pre- and post-radiotherapy with18FDG PET-CT scans at a median interval of 71 days. All of the patients were followed clinically and radiographically after a mean period of 342 days for assessment of local control or failure rates. Change in size (sum of maximum orthogonal diameters) was correlated with that of maximum standard uptake value (SUV) of the primary lung cancer before and after conventional radiotherapy. RESULTS: There was a significant reduction in both SUV and size of the primary cancer after radiotherapy (p < 0.00005). Among the 20 surviving patients, the sensitivity, specificity, and accuracy using PET (SUV) were 94%, 50%, 90% respectively and the corresponding values using and CT (size criteria) were 67%, 50%, and 65% respectively. The metabolic change (SUV) was highly correlated with the change in size by a quadratic function. In addition, the mean percentage metabolic change was significantly larger than that of size change (62.3 +/- 32.7% vs 47.1 +/- 26.1% respectively, p = 0.03) CONCLUSION: Correlating and incorporating metabolic change by PET into size change by concomitant CT is more sensitive in assessing therapeutic response than CT alone.  (+info)

MASH1: a useful marker in differentiating pulmonary small cell carcinoma from Merkel cell carcinoma. (2/445)

 (+info)

ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. (3/445)

 (+info)

Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. (4/445)

 (+info)

Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer. (5/445)

 (+info)

Severe hypertension and hypokalemia as first clinical manifestations in ectopic Cushing's syndrome. (6/445)

 (+info)

Epidermal growth factor receptor mutations in small cell lung cancer. (7/445)

 (+info)

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. (8/445)

 (+info)